Affinage

ANXA5

Annexin A5 · UniProt P08758

Length
320 aa
Mass
35.9 kDa
Annotated
2026-04-28
66 papers in source corpus 19 papers cited in narrative 19 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ANXA5 (Annexin A5) is a Ca²⁺-dependent phospholipid-binding protein that preferentially binds phosphatidylserine (PS) on cell surfaces and forms two-dimensional crystalline arrays essential for its anticoagulant activity; an ANXA5 mutant that binds PS but cannot form 2D lattices fails to inhibit coagulation, establishing lattice formation as the mechanistic basis of its hemostatic function (PMID:27178140). At the placental syncytiotrophoblast, ANXA5 provides an anticoagulant shield, and the M2 promoter haplotype reduces ANXA5 transcription to ~40% of normal levels in placental tissue, predisposing to perivillous fibrin deposition and recurrent pregnancy loss (PMID:17339269, PMID:24140079). Beyond anticoagulation, ANXA5 activates the ERK→Nrf2/HO-1 antioxidant signaling axis to protect against oxidative stress, inhibits monocyte adhesion and transmigration across activated endothelium via PS binding to attenuate atherosclerotic inflammation, and functions as an endogenous inhibitor of protein kinase C (PMID:31404886, PMID:25214012, PMID:7672695).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 1989 High

    Establishing ANXA5 as a member of the annexin family with a defined chromosomal locus (4q28-q32) provided the genomic framework for subsequent functional and genetic studies.

    Evidence Southern blot analysis of somatic cell hybrids and in situ chromosome hybridization

    PMID:2534288

    Open questions at the time
    • No functional characterization at this stage
    • Regulatory elements of the locus not yet mapped
  2. 1990 Medium

    Localizing ANXA5 to syncytiotrophoblast microvilli and cortical cytoplasm established the subcellular compartment where it could function as a placental anticoagulant.

    Evidence Immunocytochemistry with light and electron microscopy of human placental tissue

    PMID:2148197

    Open questions at the time
    • Mechanism of anticoagulant action at this surface not yet defined
    • Dynamics of ANXA5 recruitment to microvilli unknown
  3. 1995 Medium

    Identifying ANXA5 as a protein kinase C inhibitor whose transcription is suppressed in carcinoma cells revealed a potential tumor-suppressive signaling role beyond its membrane-binding properties.

    Evidence Northern blot, in situ hybridization, and immunohistochemistry in cervical/endometrial carcinoma vs. normal tissue

    PMID:7672695

    Open questions at the time
    • Direct biochemical mechanism of PKC inhibition not dissected
    • Causal link between ANXA5 loss and tumorigenesis not established
  4. 2007 High

    Discovery that the M2 promoter haplotype reduces ANXA5 transcription to ~37–42% of normal and associates with recurrent pregnancy loss provided the first mechanistic genetic link between ANXA5 expression and obstetric thrombotic complications.

    Evidence Luciferase reporter assays and case-control genetic study across multiple populations

    PMID:17339269

    Open questions at the time
    • Tissue-level validation of reduced expression not yet performed
    • Contribution of paternal vs. maternal genotype unclear
  5. 2010 Medium

    Allele-specific mRNA quantification in heterozygous placentas confirmed that the M2 haplotype reduces ANXA5 expression by ~42% in the relevant tissue, validating the reporter assay findings in vivo.

    Evidence Allele-specific RT-PCR and Western blot in human placental tissue

    PMID:20805002

    Open questions at the time
    • Whether reduced expression crosses a threshold for clinical thrombosis not determined
    • Protein-level quantification at the cell surface not performed
  6. 2013 Medium

    Demonstrating that fetal (placental) M2 genotype correlates with perivillous fibrin deposition more than maternal genotype established that ANXA5 functions locally at the feto-maternal interface to prevent thrombosis.

    Evidence qRT-PCR, Western blot, immunostaining, and histological assessment of pre-eclamptic placentas

    PMID:24140079

    Open questions at the time
    • Whether exogenous ANXA5 can rescue the M2-associated phenotype in human tissue untested
    • Contributions of other annexins at the same interface not assessed
  7. 2014 Medium

    Showing that exogenous ANXA5 reduces plaque macrophage content and inhibits monocyte adhesion/transmigration via PS binding extended its anti-inflammatory role beyond the placenta to atherosclerosis.

    Evidence ApoE−/− mouse atherosclerosis model with collar placement and in vitro flow chamber assays on TNFα-activated endothelium

    PMID:25214012

    Open questions at the time
    • Whether endogenous ANXA5 levels modulate atherosclerosis in vivo not tested
    • Receptor or signaling target on monocytes not identified
  8. 2016 High

    Using an ANXA5 mutant that binds PS but cannot form 2D arrays revealed that lattice formation—not merely PS binding—is the mechanistic requirement for ANXA5's anticoagulant activity, resolving a longstanding question about how ANXA5 inhibits coagulation.

    Evidence Injection of wild-type vs. lattice-deficient recombinant ANXA5 in AnxA5-deficient mice with in vivo bleeding and in vitro coagulation assays

    PMID:27178140

    Open questions at the time
    • Structural details of the 2D array at atomic resolution not resolved
    • Whether 2D array formation is also required for non-coagulant functions unknown
  9. 2016 Medium

    ANXA5 knockdown in hepatocarcinoma cells reduced proliferation, migration, and invasion specifically through the ERK2/p-ERK2/c-Jun pathway, identifying ANXA5 as an upstream activator of ERK signaling in cancer cell biology.

    Evidence shRNA knockdown with pathway inhibitor experiments, transwell and adhesion assays in Hca-F cells

    PMID:27697636

    Open questions at the time
    • Direct binding partner linking ANXA5 to ERK2 activation not identified
    • Relevance to human cancer not validated
  10. 2019 Medium

    ANXA5 overexpression activated the ERK→Nrf2/HO-1/NQO1 antioxidant pathway and protected testicular cells from oxidative stress, with ERK inhibition fully reversing the effect, establishing a defined ANXA5→ERK→Nrf2 signaling axis for cytoprotection.

    Evidence Overexpression and knockdown in Leydig/Sertoli cells with ERK inhibitor rescue, DHE staining, and Western blot

    PMID:31404886

    Open questions at the time
    • How ANXA5 activates ERK phosphorylation mechanistically is unknown
    • Whether this axis operates in non-testicular tissues not established
  11. 2020 Medium

    miR-506-3p was validated as a direct upstream regulator of ANXA5, with miR-506-3p binding the ANXA5 3′UTR to suppress expression and thereby aggravate oxidative stress through loss of Nrf2/HO-1 signaling.

    Evidence Luciferase reporter target validation, miRNA agomir injection in rats, rescue with recombinant ANXA5

    PMID:33354277

    Open questions at the time
    • Whether miR-506-3p regulation of ANXA5 is relevant in placental or vascular contexts unknown
    • Other miRNAs targeting ANXA5 not systematically assessed
  12. 2023 Medium

    Identification of the MIR4697HG lncRNA→FUS→ANXA5 axis in endothelial cells revealed a new upstream regulatory pathway controlling ANXA5 expression to protect against ox-LDL-induced endothelial dysfunction.

    Evidence RNA pull-down, Co-IP for FUS–ANXA5 interaction, overexpression/knockdown rescue in HUVECs, and ApoE−/− mouse model

    PMID:38082058

    Open questions at the time
    • Whether FUS directly stabilizes ANXA5 mRNA or protein is unclear
    • Co-IP interaction between FUS and ANXA5 protein requires reciprocal validation and domain mapping

Open questions

Synthesis pass · forward-looking unresolved questions
  • The molecular mechanism by which ANXA5 activates ERK signaling, the structural basis of its 2D array at atomic resolution on biological membranes, and whether its anticoagulant lattice-forming function is required for its anti-inflammatory and cytoprotective roles remain unresolved.
  • No direct binding partner linking ANXA5 to ERK activation identified
  • No high-resolution structure of the 2D array on a native membrane
  • Whether 2D lattice formation is required for non-coagulant functions untested

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0008289 lipid binding 5 GO:0098772 molecular function regulator activity 3
Localization
GO:0005576 extracellular region 3 GO:0005886 plasma membrane 3 GO:0005829 cytosol 1
Pathway
R-HSA-109582 Hemostasis 2 R-HSA-162582 Signal Transduction 2 R-HSA-8953897 Cellular responses to stimuli 2 R-HSA-168256 Immune System 1
Partners
ALPLANXA6FUS

Evidence

Reading pass · 19 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1989 The human ANXA5 gene (endonexin II, ENX2) was mapped to chromosome 4q28-q32 by Southern transfer analysis of human x rodent somatic cell hybrid DNAs and in situ chromosome hybridization, establishing it as a member of the Ca2+-dependent phospholipid-binding annexin gene family. Somatic cell hybrid panel Southern blotting and in situ chromosome hybridization Cytogenetics and cell genetics High 2534288
1990 ANXA5 (placental anticoagulant protein-I, PAP-I) was localized to the microvilli of placental syncytiotrophoblast cells and their cortical cytoplasm beneath the villi, establishing its specific subcellular distribution in the relevant anticoagulant compartment. Immunocytochemistry (light and electron microscopy) of human placenta Rinsho byori. The Japanese journal of clinical pathology Medium 2148197
1995 ANXA5 (calphobindin I/CPB I/Annexin V) was identified as an endogenous inhibitor of protein kinase C, and its expression was markedly suppressed at the transcriptional level in cervical and endometrial carcinoma cells compared to normal counterparts, as shown by northern blot and in situ hybridization. Northern blot, in situ hybridization, immunohistochemistry Gynecologic oncology Medium 7672695
2007 The M2 haplotype (four consecutive nucleotide substitutions) in the ANXA5 promoter reduces in vitro ANXA5 promoter activity to 37–42% of normal level as demonstrated by reporter gene (luciferase) assays, and is associated with recurrent pregnancy loss risk. Reporter gene (luciferase) assays, sequence analysis, case-control genetic study Human molecular genetics High 17339269
2007 ANXA5-expressing perivascular cells (PVC) isolated using the Anxa5-LacZ fusion gene marker express pericyte-specific markers (NG2, desmin, αSMA, PDGFR-β) and stem cell marker Sca-1, and when co-cultured with endothelial cells stimulate angiogenesis (increased PECAM expression) and basement membrane deposition; in vivo grafts recruit endothelial cells and become vascularized. Cell isolation using Anxa5-LacZ reporter, immunophenotyping, co-culture assays, in vivo chorioallantoic membrane graft Experimental cell research Medium 17543301
2010 The M2 allele of ANXA5 results in an average 42% reduction in allele-specific ANXA5 mRNA levels in heterozygous placentas compared to the normal allele, directly linking the M2 promoter haplotype to reduced expression in the relevant tissue. Allele-specific mRNA quantification in placental tissue by RT-PCR, Western blot Placenta Medium 20805002
2013 In pre-eclamptic patients, placental ANXA5 mRNA and protein levels are lower in M2 haplotype carriers, and placental (fetal) M2 genotype correlates more closely than maternal M2 with severity of perivillous fibrin deposition, indicating ANXA5 functions locally at the feto-maternal interface to prevent thrombosis. qRT-PCR, Western blot, immunostaining, histological examination of placentas Placenta Medium 24140079
2014 Exogenous ANXA5, which binds cell-surface phosphatidylserine (PS), reduces plaque macrophage content in advanced atherosclerotic lesions in apoE−/− mice; in vitro, ANXA5 inhibits capture, rolling, adhesion, and transmigration of peripheral blood mononuclear cells on TNF-α-activated endothelial cells, establishing an anti-inflammatory mechanism via PS binding. In vivo mouse atherosclerosis model (collar placement), immunohistochemistry, in vitro flow chamber adhesion assay Journal of cellular and molecular medicine Medium 25214012
2016 ANXA5 requires the ability to form two-dimensional (2D) arrays on the cell surface (via PS binding) to inhibit hemostasis: pharmacological concentrations of wild-type ANXA5 (1 µM) induced bleeding in mice, while an ANXA5 mutant that binds PS but cannot form 2D arrays failed to cause bleeding or delay coagulation, demonstrating that 2D lattice formation is necessary for ANXA5's anticoagulant function. AnxA5-deficient mice, injection of recombinant WT and mutant ANXA5, in vivo bleeding assay, in vitro coagulation assays Cells, tissues, organs High 27178140
2016 Knockdown of ANXA5 in murine hepatocarcinoma Hca-F cells reduces proliferation, migration, invasion, and lymph node adhesion; mechanistically, ANXA5 acts specifically via the ERK2/p-ERK2/c-Jun/p-c-Jun(Ser73) pathway and regulates E-cadherin levels, rather than through p38MAPK, JNK, or AKT pathways. shRNA knockdown, CCK-8, Boyden transwell, in situ LN adhesion assay, Western blot, qRT-PCR, pathway inhibitor experiments Biomedicine & pharmacotherapy Medium 27697636
2017 ANXA5 and TNAP co-incorporated into proteoliposomes (matrix vesicle mimetics) induce local changes in membrane fluidity detectable by AFM; ANXA5-containing proteoliposomes bind type II collagen, and combined TNAP+ANXA5 proteoliposomes show lower collagen affinity than ANXA5 alone, establishing ANXA5's role in membrane organization and matrix interactions during biomineralization. Atomic force microscopy of proteoliposomes, reconstitution of ANXA5 and TNAP into lipid vesicles, collagen binding assay Biochimica et biophysica acta. Biomembranes Medium 28549727
2018 Micromolar Zn2+ stimulates ANXA5 transcription, raising ANXA5 protein surface abundance on BeWo and HUVEC cells, resulting in prolonged coagulation times; Zn2+-fed AnxA5-deficient pregnant mice showed a trend toward increased litter size, linking ANXA5 transcriptional upregulation to anticoagulant function and pregnancy outcome. Cell culture (BeWo, HUVEC), Western blot, coagulation assay, AnxA5-deficient mouse model with dietary Zn2+ supplementation Reproductive sciences Medium 29716435
2019 ANXA5 overexpression in testicular Leydig and Sertoli cells activates the Nrf2/HO-1/NQO1 antioxidant pathway via ERK phosphorylation, and attenuates DBP-induced oxidative stress; ERK inhibition reverses the protective effect of ANXA5, establishing the ANXA5→ERK→Nrf2 signaling axis. Overexpression and knockdown in cell culture, DHE staining, ELISA, Western blot, ERK inhibitor experiments Environmental toxicology and pharmacology Medium 31404886
2019 AnxA5 domain specifically recognizes and binds to cells injured by hypoxia (PS-exposing dead/dying cells); a SDF-1-AnxA5 fusion protein accumulates at infarcted myocardium after peripheral vein injection in mice, reduces apoptosis, enhances angiogenesis, reduces infarct size, and improves cardiac function, demonstrating ANXA5's PS-targeting function can be exploited for cardiac drug delivery. Receptor competition assay, binding membrane assay, immunofluorescence, mouse MI model with IV injection, echocardiography Journal of cellular and molecular medicine Medium 31468674
2020 miR-506-3p directly binds to ANXA5 mRNA and reduces ANXA5 expression; overexpression of miR-506-3p decreases ANXA5 protein levels and downregulates the Nrf2/HO-1 signaling pathway, aggravating DBP-induced testicular oxidative stress injury; exogenous recombinant ANXA5 reverses these effects, establishing ANXA5 as a direct target of miR-506-3p in testicular oxidative stress regulation. miRNA agomir injection in rats, luciferase reporter (miRNA target validation), Western blot, immunohistochemistry, CCK-8, flow cytometry Oxidative medicine and cellular longevity Medium 33354277
2020 ANXA5 silencing in B-ALL cells increases DEX-induced apoptosis and significantly elevates cleaved Caspase 3 and Caspase 9 levels, establishing that ANXA5 confers glucocorticoid resistance by suppressing caspase-dependent apoptosis. siRNA knockdown, flow cytometry (apoptosis), Western blot (caspase cleavage) Pediatric hematology and oncology Low 33231128
2021 In rat pituitary gland, GnRH induces Nr4a3 mRNA expression (peak at proestrus), after which Anxa5 mRNA rises and suppresses Nr4a3, with Anxa5 elevation coinciding with increased Fshb mRNA; GnRH antagonist abolishes Nr4a3 induction, establishing a sequential GnRH→Nr4a3→Anxa5 regulatory axis controlling FSH-beta expression. RT-PCR, GnRH antagonist treatment in vivo, analysis across estrous cycle time points The Journal of reproduction and development Medium 33840679
2023 LncRNA MIR4697HG binds FUS protein (shown by RNA pull-down), and FUS in turn interacts with ANXA5 (shown by Co-IP); MIR4697HG overexpression upregulates FUS, which promotes ANXA5 expression to protect endothelial cells from ox-LDL-induced apoptosis, oxidative stress, and adhesion molecule release; ANXA5 knockdown reverses the protective effect of FUS overexpression. RNA pull-down, Co-immunoprecipitation, overexpression/knockdown in HUVECs, ApoE−/− mouse atherosclerosis model Biochemical genetics Medium 38082058
2025 In Duchenne muscular dystrophy (DMD) skeletal muscle cells, ANXA5 and ANXA6 fail to upregulate in response to mechanical stress (unlike control cells), suggesting ANXA5 normally participates in an adaptive membrane repair response in skeletal muscle; DMD cells show defective membrane resealing and massive IgG uptake confirming impaired repair. Shear stress-based injury assay, live-cell imaging of GFP-tagged annexins, Western blot, immunohistochemistry of patient biopsies bioRxiv (preprint)preprint Low bio_10.1101_2025.09.23.677988

Source papers

Stage 0 corpus · 66 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1978 The amino-acid sequence of S-100 protein (PAP I-b protein) and its relation to the calcium-binding proteins. European journal of biochemistry 351 710399
1998 Interaction of mouse polycomb-group (Pc-G) proteins Enx1 and Enx2 with Eed: indication for separate Pc-G complexes. Molecular and cellular biology 112 9584197
1995 Pancreatitis-associated protein I (PAP I), an acute phase protein induced by cytokines. Identification of two functional interleukin-6 response elements in the rat PAP I promoter region. The Journal of biological chemistry 100 7545677
2007 A common haplotype of the annexin A5 (ANXA5) gene promoter is associated with recurrent pregnancy loss. Human molecular genetics 93 17339269
2002 Coordinate regulation of secretory stress proteins (PSP/reg, PAP I, PAP II, and PAP III) in the rat exocrine pancreas during experimental acute pancreatitis. The Journal of surgical research 91 12121700
1995 Differential binding of Lrp to two sets of pap DNA binding sites mediated by Pap I regulates Pap phase variation in Escherichia coli. The EMBO journal 83 8846772
1999 Pokeweed antiviral protein isoforms PAP-I, PAP-II, and PAP-III depurinate RNA of human immunodeficiency virus (HIV)-1. Biochemical and biophysical research communications 67 10403789
2009 Haplotype M2 in the annexin A5 (ANXA5) gene and the occurrence of obstetric complications. Thrombosis and haemostasis 56 19652881
2001 Cdx1 promotes cellular growth of epithelial intestinal cells through induction of the secretory protein PAP I. European journal of cell biology 45 11302520
2010 Reduced allele specific annexin A5 mRNA levels in placentas carrying the M2/ANXA5 allele. Placenta 41 20805002
2007 Isolated Anxa5+/Sca-1+ perivascular cells from mouse meningeal vasculature retain their perivascular phenotype in vitro and in vivo. Experimental cell research 40 17543301
2019 The role of ANXA5 in DBP-induced oxidative stress through ERK/Nrf2 pathway. Environmental toxicology and pharmacology 31 31404886
2017 Topographic analysis by atomic force microscopy of proteoliposomes matrix vesicle mimetics harboring TNAP and AnxA5. Biochimica et biophysica acta. Biomembranes 31 28549727
2014 AnxA5 reduces plaque inflammation of advanced atherosclerotic lesions in apoE(-/-) mice. Journal of cellular and molecular medicine 31 25214012
2019 The bifunctional SDF-1-AnxA5 fusion protein protects cardiac function after myocardial infarction. Journal of cellular and molecular medicine 26 31468674
1995 Suppression of calphobindin I (CPB I) production in carcinoma of uterine cervix and endometrium. Gynecologic oncology 26 7672695
2019 Nerve Injury-Induced Neuronal PAP-I Maintains Neuropathic Pain by Activating Spinal Microglia. The Journal of neuroscience : the official journal of the Society for Neuroscience 25 31744864
2013 Contribution of fetal ANXA5 gene promoter polymorphisms to the onset of pre-eclampsia. Placenta 24 24140079
2013 Genotyping analyses for polymorphisms of ANXA5 gene in patients with recurrent pregnancy loss. Fertility and sterility 21 23850300
2016 Anxa5 mediates the in vitro malignant behaviours of murine hepatocarcinoma Hca-F cells with high lymph node metastasis potential preferentially via ERK2/p-ERK2/c-Jun/p-c-Jun(Ser73) and E-cadherin. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 19 27697636
2012 The M2 haplotype in the ANXA5 gene is an independent risk factor for idiopathic small-for-gestational age newborns. Molecular human reproduction 16 22679123
2020 Overexpression of miR-506-3p Aggravates DBP-Induced Testicular Oxidative Stress in Rats by Downregulating ANXA5 via Nrf2/HO-1 Signaling Pathway. Oxidative medicine and cellular longevity 14 33354277
2012 Combining [11C]-AnxA5 PET imaging with serum biomarkers for improved detection in live mice of modest cell death in human solid tumor xenografts. PloS one 14 22870292
2001 Pancreatitis associated protein I (PAP-I) alters adhesion and motility of human melanocytes and melanoma cells. The Journal of investigative dermatology 14 11231317
1996 Mechanism of PAP I gene induction during hepatocarcinogenesis: clinical implications. British journal of cancer 14 8956791
2016 Lessons From the EThIGII Trial: Proper Putative Benefit Assessment of Low-Molecular-Weight Heparin Treatment in M2/ANXA5 Haplotype Carriers. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 13 27418639
2015 M2/ANXA5 haplotype as a predisposition factor in Malay women and couples experiencing recurrent spontaneous abortion: a pilot study. Reproductive biomedicine online 13 25682309
2014 Involvement of ANXA5 and ILKAP in susceptibility to malignant melanoma. PloS one 13 24743186
2013 Independent association of the M2/ANXA5 haplotype with recurrent pregnancy loss (RPL) in PCOS patients. Metabolism: clinical and experimental 13 23498654
2003 The Polycomb-group protein ENX-2 interacts with ZAP-70. Immunology letters 12 12600746
1999 PAP I interacts with itself, PAP II, PAP III, and lithostathine/regIalpha. Molecular cell biology research communications : MCBRC 12 10662590
2022 Research progress on ANXA5 in recurrent pregnancy loss. Journal of reproductive immunology 11 35964539
2016 Skin Wound Repair Is Not Altered in the Absence of Endogenous AnxA1 or AnxA5, but Pharmacological Concentrations of AnxA4 and AnxA5 Inhibit Wound Hemostasis. Cells, tissues, organs 11 27178140
1989 The human endonexin II (ENX2) gene is located at 4q28----q32. Cytogenetics and cell genetics 11 2534288
2015 ANXA5 level is linked to in vitro and in vivo tumor malignancy and lymphatic metastasis of murine hepatocarcinoma cell. Future oncology (London, England) 10 26615672
2012 The annexin A5 protective shield model revisited: inherited carriage of the M2/ANXA5 haplotype in placenta as a predisposing factor for the development of obstetric antiphospholipid antibodies. Lupus 10 22635237
2018 Maternal carriers of the ANXA5 M2 haplotype are exposed to a greater risk for placenta-mediated pregnancy complications. Journal of assisted reproduction and genetics 9 29497952
2021 Development of Tg(UAS:SEC-Hsa.ANXA5-YFP,myl7:RFP); Casper(roy-/-,nacre-/-) Transparent Transgenic In Vivo Zebrafish Model to Study the Cardiomyocyte Function. Cells 8 34440732
2005 The value of biliary amylase and Hepatocarcinoma-Intestine-Pancreas/Pancreatitis-associated Protein I (HIP/PAP-I) in diagnosing biliary malignancies. Clinical biochemistry 8 15885230
2021 Genetic analysis of ANXA5 haplotype and its effect on recurrent pregnancy loss. Molecular medicine reports 7 34878150
2013 The haplotype M2 of the ANXA5 gene is not associated with antitrophoblast antibodies. Journal of assisted reproduction and genetics 7 23529182
1995 Identification of a transcriptional regulatory region of the rat pancreatitis-associated protein I (PAP I) gene that confers tissue specificity. The Biochemical journal 7 7487908
2024 ANXA5: A Key Regulator of Immune Cell Infiltration in Hepatocellular Carcinoma. Medical science monitor : international medical journal of experimental and clinical research 6 38824386
2021 Sequential preovulatory expression of a gonadotropin-releasing hormone-inducible gene, Nr4a3, and its suppressor Anxa5 in the pituitary gland of female rats. The Journal of reproduction and development 6 33840679
2025 ANXA5: related mechanisms of osteogenesis and additional biological functions. Frontiers in cell and developmental biology 5 40342928
2023 LncRNA MIR4697HG Alleviates Endothelial Cell Injury and Atherosclerosis Progression in Mice via the FUS/ANXA5 Axis. Biochemical genetics 5 38082058
2020 Glucocorticoid resistance induced by ANXA5 overexpression in B-cell acute lymphoblastic leukemia. Pediatric hematology and oncology 5 33231128
2018 Micromolar Zinc in Annexin A5 Anticoagulation as a Potential Remedy for RPRGL3-Associated Recurrent Pregnancy Loss. Reproductive sciences (Thousand Oaks, Calif.) 5 29716435
2018 Correlation of single nucleotide polymorphisms in the promoter region of the ANXA5 (annexin A5) gene with recurrent miscarriages in women of Greek origin. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 5 30196743
2014 Disruption of murine Tcte3-3 induces tissue specific apoptosis via co-expression of Anxa5 and Pebp1. Computational biology and chemistry 5 25462330
2011 Continuous stress-induced dopamine dysregulation augments PAP-I and PAP-II expression in melanotrophs of the pituitary gland. Biochemical and biophysical research communications 5 21329657
1997 Characterization of a silencer regulatory element in the rat PAP I gene which confers tissue-specific expression and is promoter-dependent. Archives of biochemistry and biophysics 5 9126283
2017 The association between annexin A5 (ANXA5) gene polymorphism and left ventricular hypertrophy (LVH) in Chinese endogenous hypertension patients. Medicine 4 29095261
2024 SSL5-AnxA5 Fusion Protein Constructed Based on Human Atherosclerotic Plaque scRNA-Seq Data Preventing the Binding of Apoptotic Endothelial Cells, Platelets, and Inflammatory Cells. Biomedicines 3 39857592
2022 Association between ANXA5 haplotypes and the risk of recurrent pregnancy loss. The Journal of international medical research 3 35899914
2019 The relevance of ANXA5 genetic variants on male fertility. Journal of assisted reproduction and genetics 2 31190166
1990 [Morphological detection of placental anticoagulant protein-I (PAP-I) in human placenta]. Rinsho byori. The Japanese journal of clinical pathology 2 2148197
2025 Integrative analysis of single-cell and bulk RNA sequencing reveals the oncogenic role of ANXA5 in gastric cancer and its association with drug resistance. Frontiers in immunology 1 40124374
2025 Identification of functional SNP associated with sperm quality in porcine ANXA5 that contributes to the growth of immature Sertoli cell. Frontiers in veterinary science 1 40438404
2018 Antiphospholipid Antibodies in a General Obstetric Population: Clinical Impact on Pregnancy Outcome and Relationship with the M2 Haplotype in the Annexin A5 (ANXA5) Gene. Hamostaseologie 1 30304747
1999 Mouse monoclonal antibodies against Phytolacca americana antiviral protein PAP I. Hybridoma 1 10571267
2026 Conformation of CD40LG and ANXA5 as Key Events of 2,7-Dibromocarbazole-Induced Cardiotoxicity Using in Vivo and in Vitro Models. Environmental science & technology 0 41610337
2026 COL10A1 transcriptional regulation of ANXA5-mediated ferroptosis is involved in malignant progression of head and neck squamous cell carcinoma. Translational cancer research 0 41815119
2025 Single nucleotide variations in the ANXA5 promoter regulated piglet weight in the Min pig. Frontiers in veterinary science 0 41190166
2025 Remdesivir alleviates inflammation and tissue damage in experimental colitis via AnxA5 Signaling. International immunopharmacology 0 41411728
2024 ANXA5 and VEGFA Gene Variants in Women with Early Pregnancy Losses from North Macedonia. Balkan journal of medical genetics : BJMG 0 39263641